Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Intervacc AB's EBITDA for the
three
months ended in Mar. 2026 was kr-17.52 Mil. Intervacc AB's Revenue for the
three
months ended in Mar. 2026 was kr3.37 Mil. Therefore, Intervacc AB's EBITDA margin for the quarter that ended in Mar. 2026 was -519.26%.
Intervacc AB (OSTO:IVACC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Intervacc AB EBITDA Margin % Related Terms
Intervacc AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Intervacc AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IVACC vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Intervacc AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Intervacc AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (OSTO:IVACC) has a EBITDA Margin % of -519.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #650 out of 940 companies in the Biotechnology industry, placing it in the top 69.1%.
Is Intervacc AB's EBITDA Margin % too high?
Intervacc AB's current EBITDA Margin % is -519.26%. Based on the distribution chart, Intervacc AB ranks #650 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #650 out of 940 companies for EBITDA Margin %. This places Intervacc AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Intervacc AB and its competitors. Intervacc AB's current EBITDA Margin % is -519.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Based on GuruFocus' analysis, Intervacc AB (OSTO:IVACC) is currently considered Fairly Valued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.12 — trading 0.7% above its estimated fair value. The current EBITDA Margin % is -519.26%. Intervacc AB's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Intervacc AB (OSTO:IVACC), the current EBITDA Margin % is -519.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (OSTO:IVACC) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of kr1.12 is trading 0.7% above its estimated GF Value™ of kr1.11.
GuruFocus considers Intervacc AB to be Fairly Valued.
Key valuation signals for OSTO:IVACC:
EBITDA Margin %: -519.26%
GF Value™: kr1.11 vs. price of kr1.12 (0.7% above fair value)
No single metric tells the full story. See the OSTO:IVACC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
64GF Score
Get the complete analysis for OSTO:IVACC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IVACC has been successfully added to your 
